Nurix Therapeutics Inc (NRIX)

Currency in USD
9.69
-0.38(-3.77%)
Real-time Data·
NRIX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.5810.09
52 wk Range
8.1829.56
Key Statistics
Prev. Close
10.07
Open
10.01
Day's Range
9.58-10.09
52 wk Range
8.18-29.56
Volume
222.14K
Average Volume (3m)
854.44K
1-Year Change
-49.68%
Book Value / Share
5.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.83
Upside
+207.88%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Nurix Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Nurix Therapeutics Inc Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics Inc SWOT Analysis


Promising Pipeline
Explore Nurix's innovative protein degradation platform and its lead candidate bexobrutideg, showing encouraging results in CLL and NHL clinical trials
Financial Health
Despite operating losses, Nurix maintains a strong cash position of $609.6 million, funding operations into 2027 with analyst targets ranging from $16 to $41
Strategic Expansion
Delve into Nurix's move beyond oncology into autoimmune diseases, potentially broadening its market reach and diversifying revenue streams
Competitive Landscape
Learn about Nurix's partnerships with major pharmaceutical companies and how it navigates intense competition in the rapidly evolving biotechnology secto
Read full SWOT analysis

Compare NRIX to Peers and Sector

Metrics to compare
NRIX
Peers
Sector
Relationship
P/E Ratio
−3.6x−1.1x−0.5x
PEG Ratio
−0.35−0.060.00
Price/Book
1.6x2.2x2.6x
Price / LTM Sales
8.3x9.2x3.3x
Upside (Analyst Target)
197.9%326.4%43.4%
Fair Value Upside
Unlock7.2%7.1%Unlock

Analyst Ratings

16 Buy
2 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.83
(+207.88% Upside)

Earnings

Latest Release
Jul 09, 2025
EPS / Forecast
-0.52 / -0.714
Revenue / Forecast
44.06M / 16.90M
EPS Revisions
Last 90 days

NRIX Income Statement

People Also Watch

247.00
AVAV
-4.86%
18.22
SRPT
+1.42%
51.72
BMNR
+25.30%
7.085
BBAI
+7.19%
157.98
CRCL
+3.30%

FAQ

What Stock Exchange Does Nurix Trade On?

Nurix is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Nurix?

The stock symbol for Nurix is "NRIX."

What Is the Nurix Market Cap?

As of today, Nurix market cap is 737.74M.

What Is Nurix's Earnings Per Share (TTM)?

The Nurix EPS (TTM) is -2.60.

When Is the Next Nurix Earnings Date?

Nurix will release its next earnings report on 08 Oct 2025.

From a Technical Analysis Perspective, Is NRIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nurix Stock Split?

Nurix has split 0 times.

How Many Employees Does Nurix Have?

Nurix has 286 employees.

What is the current trading status of Nurix (NRIX)?

As of 08 Aug 2025, Nurix (NRIX) is trading at a price of 9.69, with a previous close of 10.07. The stock has fluctuated within a day range of 9.58 to 10.09, while its 52-week range spans from 8.18 to 29.56.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.